High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia
- Authors
- Ko, Sun-Young; Park, Chan-Jeoung; Park, Sang-Hyuk; Cho, Young-Uk; Jang, Seongsoo; Seo, Eul-ju; Kim, Nayoung; Kim, Dae-Young; Koh, Kyung Nam; Im, Ho Joon; Seo, Jong-Jin; Chi, Hyun-Sook
- Issue Date
- 1월-2014
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- VLA-4; CXCR4; Acute lymphoblastic leukemia; Adult; Survival; Prognostic marker
- Citation
- LEUKEMIA RESEARCH, v.38, no.1, pp.65 - 70
- Indexed
- SCIE
SCOPUS
- Journal Title
- LEUKEMIA RESEARCH
- Volume
- 38
- Number
- 1
- Start Page
- 65
- End Page
- 70
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/99674
- DOI
- 10.1016/j.leukres.2013.10.016
- ISSN
- 0145-2126
- Abstract
- Data regarding the prognostic significance of CXCR4 and VLA-4 in ALL are limited. Especially, VLA-4 has not been evaluated at the time of diagnosis in both adult and childhood ALL patients. We prospectively analyzed the expression of VLA-4 and CXCR4 in 54 patients (VLA-4 in 29 adults and 25 children and CXCR4 in 22 adults and 24 children) newly diagnosed with ALL by flow cytometry. Expression levels of VLA-4 and CXCR4 were not different between adults and children with ALL. High CXCR4 and low VLA-4 expression each correlated with worse prognosis in adults; patients with high CXCR4 expression had shorter disease-free survival (p =0.01) and overall survival (p = 0.04) and patients with low VLA-4 expression had shorter disease-free survival (p = 0.02). Expression levels of CXCR4 and VLA-4 did not predict patient prognosis in children. Analysis of CXCR4 and VLA-4 expression at diagnosis in adults with ALL can provide useful information on patient prognosis. (C) 2013 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.